Insights - Investors are again infatuated with Intercept Pharmaceuticals (ICPT), which on Monday reported further results from a mid-stage study of drug candidate obeticholic acid. ICPT rocketed higher by 400% … Continue Reading
Read NowInsights - In which we suggest taking profit and/or selling Calls on TKMR equity position. A handy return from $11.50 in July.
Read NowRecap - BOOM! Shares of Tekmira Pharmaceuticals (TKMR) climbed from $14 to $20 into Friday’s close after the FDA removed a clinical hold on the company’s Ebola therapeutic, essentially enabling its … Continue Reading
Read NowResearch - Orexigen Therapeutics (OREX) on Thursday reported second quarter results. We’re bullish on OREX in the near-term, but some revelations on the company’s conference call work against the … Continue Reading
Read NowInsights - Investors and analysts expected more out of Ariad Pharmaceuticals’ (ARIA) Iclusig in the second quarter and punished the stock when sales from the company’s only … Continue Reading
Read NowInsights - Despite encouraging quarterly U.S. sales from its Eylea treatment for macular degeneration, reported on Tuesday morning, Regeneron Pharmaceuticals’ (REGN) shares were down more than two … Continue Reading
Read NowInsights - Tekmira Pharmaceuticals (TKMR) was the momentum stock of the week as the spread of Ebola continues in Guinea, Liberia and Sierra Leone, and two infected Americans … Continue Reading
Read Now
